Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
Eric J LoweAnne F ReillyMegan S LimThomas G GrossLauren SaguiligDonald A BarkauskasRui WuSarah AlexanderCatherine M BollardPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Arm CZ of ANHL12P1 demonstrated that the addition of CZ to standard treatment prevented relapses during therapy for children with ALCL, MDD predicted EFS, and the addition of CZ resulted in unexpected thromboembolic events. Overall survival and EFS rates are consistent with the highest reported outcomes for children with ALCL.